Category: Trick or Trade

Alterity Therapeutics: Treating Neurodegenerative Diseases?

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate.    Alterity Therapeutics Yesterday the stock soared for a firm called Alterity Therapeutics (ATHE) closing at $3.43 UP $2.08. We found that this firm’s market cap is $3.72 billion which boosted our curiosity to learn more about the nature of the news that rallied the stock and the firm’s business.       …

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Edesa Biotech Filed an IND for EB05 Edesa Biotech (EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. FDA for the initiation of a Phase 2/3 clinical study of its investigational drug EB05. Edesa has recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accelerate site selection and initiate …
Could Arbutus Biopharma’s Patent Harm Moderna?

Could Arbutus Biopharma’s Patent Harm Moderna?

Arbutus Biopharma and Moderna’s Patent Challenge Arbutus Biopharma (ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering and developing a cure for patients suffering from chronic hepatitis B infection. The stock has been in the Aggressive Table of the Prohost Portfolio for a while and has recently rallied, doubling and tripling; it continues to soar. Why? Because Moderna (MRNA) has lost in its attempt to …

There Is A Lot More To Say About the COVID-19 Vaccines

Pfizer and BioNTech Vaccines Were Granted FDA Fast Track Designation Against SARS-CoV-2 (COVID-19) A large Phase 2b/3 safety and efficacy study may begin as early as July 2020 Pfizer (PFE) and BioNTech (BNTX) announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed against SARS-CoV-2 (COVID-19) received Fast Track designation from the U.S. Food …

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.   Why This is Important By remaining inactive until activated by the cancers’ microenvironment’s proteases, the Probody therapeutics minimizes the active drug’s toxicity …
An Evaluation of Biotech Firms Part 4

An Evaluation of Biotech Firms Part 4

A Comprehensive Essay  Part 4 Our fair evaluation approaches of biotechnology and biopharma companies differ depending on the sizes and statuses of the firms. We reiterate our conviction that causing a selloff of development stage biotech stocks at every announcement of quarterly financial results because of lack of income is irrelevant and unfair to the firms and their stockholders. It does not make sense that …
Why Moderna Therapeutics’ Stock Is Down Today

Why Moderna Therapeutics’ Stock Is Down Today

Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin with, most, if not all, development-stage firms are yo-yo games played by day traders and investors whose strategies are buying low and selling high. These people also buy and sell on encouraging news and bad news; if their eyes happen to fall on any fundamental news.   One of …
An Evaluation of Biotech Firms Part 3

An Evaluation of Biotech Firms Part 3

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex (VRTX) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a matter of fact, we use the histories of real firms in this essay for the sake of demonstrating the above without considering the Companies’ technologies or approved …
An Evaluation of Biotech Firms Part 2

An Evaluation of Biotech Firms Part 2

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex remains our case in point. In Part 1 we acknowledged that we picked VRTX on March 18, 2011 at $44.39. The question is: …
An Evaluation of Biotech Firms Part 1

An Evaluation of Biotech Firms Part 1

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked stocks which proved to be highly successful after being condemned by erroneous evaluations from unfair analysts. Some of these firms faced problems that are not unusual for drug designing and developing firms. While trying to overcome their obstacles, the firms in question were faced with unfortunate debilitating attacks by …